1 · Remove from 503B bulks list
FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need, given that brand-name supply is no longer in shortage.
PeptiOEM · GLP-1 2026 update
Regulatory update · published 2026-06-05
GLP-1 supply after the FDA's 503B bulks proposal.
On 2026-04-30 the FDA proposed removing GLP-1 medications — semaglutide, tirzepatide, liraglutide — from the 503B bulks list. The comment period closes 2026-06-29. Here is what we have read, how it affects med spas, 503A pharmacies, and brand owners, and where OUS supply opens up.
!
Plain-English summary
If finalized, US 503B outsourcing facilities cannot compound GLP-1 from bulk substances. 503A pharmacies can still fill individual prescriptions. OUS markets are not directly affected. PeptiOEM positions its GLP-1 family for OUS distribution and research only.
What the FDA proposed
The 2026-04-30 proposal in three points.
This is not legal advice. Buyers should review primary FDA guidance and confirm with their counsel.
2 · Public comment window
The federal docket comment period is open through 2026-06-29. Stakeholders (pharmacies, clinicians, patients, manufacturers) can submit positions before the rule is finalized.
3 · Shortage resolution
FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. The 503B bulks removal reflects post-shortage status.
What changes — and what does not
Affected vs unaffected supply tracks.
| 503B outsourcing facilities | Most affected. If finalized, US 503B facilities cannot compound semaglutide, tirzepatide or liraglutide from bulk substances. Large-scale low-cost compounded GLP-1 from this channel ends. |
|---|---|
| 503A compounding pharmacies | Less directly affected. 503A pharmacies may still fill individual prescriptions for identified patients within FDA's compounding framework. Workarounds (non-standard doses, forms) may remain available in specific contexts. |
| Med spas and longevity clinics | Source shift. Med spas and clinics that relied on 503B-compounded GLP-1 will need to source via brand-name product, 503A pharmacies, or transition patients to alternative protocols. Non-GLP-1 peptides (BPC-157, Sermorelin, Ipamorelin, NAD+) remain unaffected. |
| OUS distribution markets | Not directly affected. Non-US distribution is governed by local regulators. Semaglutide is off-patent in 2026 in several countries including India and China, opening OUS supply pathways. PeptiOEM's Engine 2 (OUS-only) serves these markets. |
| Research labs (US) | Reviewed case-by-case. Research peptide supply for laboratory use is distinct from compounding. We review against current FDA guidance before quoting. |
PeptiOEM position
How we are responding.
Engine 1 keeps running, worldwide
Repair, growth-hormone-axis, longevity, beauty and cognitive peptides — BPC-157, TB-500, Sermorelin, Ipamorelin, CJC-1295, Thymosin Alpha-1, GHK-Cu, NAD+, PT-141, MOTS-c — supplied worldwide to qualified B2B and research buyers.
Engine 2 — OUS only, by destination
Tirzepatide, semaglutide, retatrutide, cagrilintide for OUS distribution markets, research, and private-label brand evaluation. We confirm destination country and buyer track before quoting. US-bound inquiries for compounding use are redirected.
FAQ
Questions buyers ask in 2026.
Is compounded GLP-1 going away entirely?
Not entirely. 503A compounding pharmacies may continue filling individual prescriptions within FDA's compounding framework. Large-scale 503B bulk compounding ends if the proposal is finalized. Workarounds in specific contexts may remain available.
Will brand-name semaglutide and tirzepatide get cheaper because of patent expiry?
Outside the US, yes — in countries where the semaglutide patent is expiring in 2026, generic-drug makers are entering the market, which generally lowers prices. Inside the US, brand-name pricing is governed by separate dynamics.
Can a US-based brand owner still build an OEM GLP-1 line?
For US distribution, no — not via 503B bulk compounding under the proposed rule. For OUS distribution (Latin America, Southeast Asia, parts of EMEA), yes — subject to local registration. PeptiOEM's Engine 2 serves OUS brand evaluation.
What should med spas plan for?
Source through licensed brand-name channels or 503A pharmacies for individual prescriptions. Diversify into non-GLP-1 peptide protocols where clinically appropriate. Engine 1 compounds remain a stable supply track for med spas worldwide.
Where can I read the FDA's primary documents?
Search "FDA 503B bulks list semaglutide tirzepatide 2026" on fda.gov and the federal docket. Public comments are open through 2026-06-29.
Get specific guidance
Bring us your destination market and we will quote what is supplyable.
We are happy to talk through Engine 1 (non-GLP-1) and Engine 2 (OUS GLP-1) options for your specific market and buyer track.